volume 26, issue 3, P347-354 2011
DOI: 10.3109/02688697.2011.638996
View full text
|
|
Share

Abstract: VPA treatment, when administered according to a protocol targeting seizure control, may result in HDAC inhibition in a small subset of patients, but does not significantly affect overall patient survival. Early administration of VPA as an adjunct to temozolomide chemotherapy may have its merits, but the optimal dosing schedule and target serum level require further investigation.